Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Registered into mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program * Women of childbearing potential: adhere to scheduled pregnancy testing as required in the Revlimid REMS program * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Histologically confirmed cutaneous T-cell non-Hodgkin lymphoma (CTCL) per World Health Organization (WHO) classification 2016 including, mycosis fungoides (MF) or Sezary syndrome (SS); phase 1 : \>= stage IIB OR \>= stage IB-IIA folliculotropic/transformed MF; expansion cohort: \>= stage IB * MF/SS stage of disease according to TNMB classification * SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria * For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society for Cutaneous Lymphomas (ISCL) should be used * Relapsed/refractory disease * Failed \>= 2 prior systemic therapies * CD30-positivity by immunohistochemistry of \>= 1% * Measurable disease per modified Severity Weighted Assessment and/or Sezary count * Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminol…